在卵巢癌患者中进行一项采用疫苗预激活的自体循环T细胞的移植的一期临床试验。
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
发表日期：2023 Sep 21
作者：
Sara Bobisse, Valentina Bianchi, Janos L Tanyi, Apostolos Sarivalasis, Edoardo Missiaglia, Rémy Pétremand, Fabrizio Benedetti, Drew A Torigian, Raphael Genolet, David Barras, Alexandra Michel, Spyridon A Mastroyannis, Emese Zsiros, Denarda Dangaj Laniti, Zoi Tsourti, Brian J Stevenson, Christian Iseli, Bruce L Levine, Daniel E Speiser, David Gfeller, Michal Bassani-Sternberg, Daniel J Powell, Carl H June, Urania Dafni, Lana E Kandalaft, Alexandre Harari, George Coukos
来源：
Nature Cancer
摘要：
我们之前已经显示出使用肿瘤脉冲树突状细胞疫苗接种增强了卵巢癌中的新抗原识别。本研究中，利用1期临床试验（NCT01312376/UPCC26810）纳入19名患者，我们展示了这种反应在随后的外源性诱导转移疫苗预处理及外体扩增自体外周血T细胞之后得到进一步恢复。治疗是安全的，并且在经历了临床效益的患者中观察到了新的新抗肽活性的表位扩展，这表明了肿瘤抗体免疫力的恢复。© 2023。本文作者授权给Springer Nature America, Inc.。
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.